Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: borax; water for injections; sodium chloride; aluminium - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: sodium chloride; borax; water for injections; aluminium - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

Canada - English - Health Canada

bavarian nordic as - inactivated rabies virus (flury lep) - powder for solution - 2.5unit - inactivated rabies virus (flury lep) 2.5unit - vaccines

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intervet international b.v. - rabies virus (inactivated) >= 2 iu/dose - suspension for injection - rabies virus, inactivated - rabies virus - cattle; dog; horse; cat; sheep

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

cipla medpro (pty) ltd - powder - 2,5 iu - each 1,0 ml dose contains purified rabies antigen (rabies virus pitman-moore strain 3218) =2,5 iu

Spain - English - HMA (Heads of Medicines Agencies)

pfizer limited - canine adenovirus 4.9 gkid50, canine distemper virus 4.7 gkid50, canine parainfluenza virus 4.6 gkid50, canine parvovirus 6.1 gkid50, leptospira interrogans serogroup canicola 32 malr, leptospira interrogans serogroup icterohaemorragiae 32 malr, rabies virus, inactivated 2 iu - suspension for injection - dogs non food - live canine distemper virus + live canine adenovirus + live parainfl.virus + live canine parvovirus + inactivated rabies + inact

Austria - English - HMA (Heads of Medicines Agencies)

pfizer limited - canine adenovirus 4.9 gkid50, canine distemper virus 4.7 gkid50, canine parainfluenza virus 4.6 gkid50, canine parvovirus 6.1 gkid50, leptospira interrogans serogroup canicola 32 malr, leptospira interrogans serogroup icterohaemorragiae 32 malr, rabies virus, inactivated 2 iu - suspension for injection - dogs non food - live canine distemper virus + live canine adenovirus + live parainfl.virus + live canine parvovirus + inactivated rabies + inact

Germany - English - HMA (Heads of Medicines Agencies)

pfizer limited - canine adenovirus 4.9 gkid50, canine distemper virus 4.7 gkid50, canine parainfluenza virus 4.6 gkid50, canine parvovirus 6.1 gkid50, leptospira interrogans serogroup canicola 32 malr, leptospira interrogans serogroup icterohaemorragiae 32 malr, rabies virus, inactivated 2 iu - suspension for injection - dogs non food - live canine distemper virus + live canine adenovirus + live parainfl.virus + live canine parvovirus + inactivated rabies + inact

Greece - English - HMA (Heads of Medicines Agencies)

pfizer limited - canine adenovirus 4.9 gkid50, canine distemper virus 4.7 gkid50, canine parainfluenza virus 4.6 gkid50, canine parvovirus 6.1 gkid50, leptospira interrogans serogroup canicola 32 malr, leptospira interrogans serogroup icterohaemorragiae 32 malr, rabies virus, inactivated 2 iu - suspension for injection - dogs non food - live canine distemper virus + live canine adenovirus + live parainfl.virus + live canine parvovirus + inactivated rabies + inact

France - English - HMA (Heads of Medicines Agencies)

pfizer limited - canine adenovirus 4.9 gkid50, canine distemper virus 4.7 gkid50, canine parainfluenza virus 4.6 gkid50, canine parvovirus 6.1 gkid50, leptospira interrogans serogroup canicola 32 malr, leptospira interrogans serogroup icterohaemorragiae 32 malr, rabies virus, inactivated 2 iu - suspension for injection - dogs non food - live canine distemper virus + live canine adenovirus + live parainfl.virus + live canine parvovirus + inactivated rabies + inact